Bernie Sanders im­plores No­vo to cut list prices of Ozem­pic, We­govy

Last year
Pharma
FDA+

Gilead pays $43M to li­cense Xilio’s IL-12 pro­gram that could turn ‘cold’ tu­mors ‘hot’

Last year
Deals

Aldeyra to run an­oth­er tri­al for its dry eye dis­ease drug as part of re­sub­mis­sion plans

Last year
R&D

Bay­er to cut 90 work­ers; Aval­o's up to $185M pri­vate place­ment

Last year
News Briefing

Sanofi's dis­tri­b­u­tion deals; As­traZeneca to sup­ply US and Chi­na in­de­pen­dent­ly; Mer­ck KGaA ex­pands in Chi­na

Last year
Manufacturing

Pela­go rais­es $58M to ex­pand on­line sub­stance use treat­ment

Last year
Health Tech

Ex­clu­sive: ADC start­up Myth­ic re­cruits Jazz ex­ec to lead com­pa­ny; Dyne’s CEO shuf­fle

Last year
Peer Review

Of the few pre­clin­i­cal IPOs, Metageno­mi keeps de­tails about IND plans close

Last year
Startups
Cell/Gene Tx

Ex­clu­sive: In­tel­li­health, a start­up work­ing with the state of Con­necti­cut to pro­vide weight loss care, rais­es $24M 

Last year
Health Tech

Up­dat­ed: FDA ap­proves Ake­bi­a's ane­mia drug af­ter say­ing no in 2022

Last year
Pharma
FDA+

Bound­less starts IPO spring with $100M list­ing for can­cer small mol­e­cules

Last year
Financing
Startups

Here's how Mod­er­na is think­ing about the fu­ture of its vac­cines

Last year
R&D

Ovid asks USP­TO to re­view Mar­i­nus' patent around treat­ment of se­ri­ous seizure con­di­tion

Last year
Pharma
Law

SK Life spot­lights epilep­sy aware­ness ef­forts like Uber rides, men­tor pro­gram and more on ‘Pur­ple Day’

Last year
Pharma
Marketing

FDA’s CDER es­tab­lish­es new cen­ter of ex­cel­lence fo­cused on quan­ti­ta­tive med­i­cine

Last year
Pharma
FDA+

On­copep­tides joins up with Vec­tor to com­mer­cial­ize blood can­cer drug Pepax­to in the Mid­dle East, North Africa

Last year
Pharma

Bio­phar­ma man­u­fac­tur­ing ‘tur­bu­lence’ boosts in­quiries for In­dia-based providers, lo­cal CD­MO ex­ecs say

Last year
Manufacturing

Gami­da Cell to go pri­vate; Stoke aims to raise $75M

Last year
News Briefing

Bris­tol My­ers to con­duct lay­offs at Mi­rati fa­cil­i­ty in Cal­i­for­nia

Last year
People

With GIP, obe­si­ty re­search is at odds

Last year
R&D
In Focus

Up­dat­ed: Mod­er­na part­ners with Black­stone on flu shots, nab­bing up to $750M in R&D fund­ing

Last year
Financing
Deals

Atai Life Sci­ences spot­lights ear­ly de­pres­sion da­ta for psy­che­del­ic ahead of big read­out

Last year
R&D

Al­tim­mune cuts he­pati­tis B pro­gram, high­lights mus­cle preser­va­tion on obe­si­ty drug in da­ta up­date

Last year
R&D

FDA ap­proves Mer­ck­'s rare PAH drug at cen­ter of $11.5B Ac­celeron deal

Last year
Pharma
FDA+
First page Previous page 179180181182183184185 Next page Last page
A service from the Financial Times